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OBJECTIVE—During energy stress, AMP-activated protein
kinase (AMPK) promotes glucose transport and glycolysis for
ATP production, while it is thought to inhibit anabolic glycogen
synthesis by suppressing the activity of glycogen synthase (GS)
to maintain the energy balance in muscle. Paradoxically, chronic
activation of AMPK causes an increase in glycogen accumulation
in skeletal and cardiac muscles, which in some cases is
associated with cardiac dysfunction. The aim of this study was
to elucidate the molecular mechanism by which AMPK activation
promotes muscle glycogen accumulation.
RESEARCH DESIGN AND METHODS—We recently gener-
ated knock-in mice in which wild-type muscle GS was replaced
by a mutant (Arg582Ala) that could not be activated by glucose-6-
phosphate (G6P), but possessed full catalytic activity and could
still be activated normally by dephosphorylation. Muscles from
GS knock-in or transgenic mice overexpressing a kinase dead
(KD) AMPK were incubated with glucose tracers and the AMPK-
activating compound 5-aminoimidazole-4-carboxamide ribonu-
cleoside (AICAR) ex vivo. GS activity and glucose uptake and
utilization (glycolysis and glycogen synthesis) were assessed.
RESULTS—Even though AICAR caused a modest inactivation of
GS, it stimulated muscle glycogen synthesis that was accompa-
nied by increases in glucose transport and intracellular [G6P].
These effects of AICAR required the catalytic activity of AMPK.
Strikingly, AICAR-induced glycogen synthesis was completely
abolished in G6P-insensitive GS knock-in mice, although AICAR-
stimulated AMPK activation, glucose transport, and total glucose
utilization were normal.
CONCLUSIONS—We provide genetic evidence that AMPK
activation promotes muscle glycogen accumulation by allosteric
activation of GS through an increase in glucose uptake and
subsequent rise in cellular [G6P]. Diabetes 60:766–774, 2011
A
MPK is a major regulator of cellular and whole-
body energy homeostasis that coordinates
metabolic pathways to balance nutrient supply
with energy demand (1–4). In response to cel-
lular stress, AMPK inhibits anabolic pathways and stim-
ulates catabolic pathways to restore cellular energy
charge. In skeletal muscle, AMPK is activated under
energy-consuming conditions such as during contraction
and also energy-depleting processes such as hypoxia,
which leads to an increase in fatty acid oxidation, glucose
uptake, and inhibition of protein synthesis (1,5). The most
well established function of AMPK activation in muscle is
to stimulate glucose transport by promoting the redis-
tribution of GLUT4 from intracellular compartments to the
cell surface (5–7).
The resulting increase in glucose transport and phos-
phorylation of glucose by hexokinase II leads to an in-
crease in the intracellular level of glucose-6-phosphate
(G6P) (8,9). G6P can be used for the synthesis of glycogen
or metabolized in the glycolytic pathway to generate ATP.
During glycogen synthesis, G6P is converted to uridine
diphosphate (UDP) glucose, and the glucosyl moiety from
UDP glucose is used to elongate a growing glycogen chain
through a-1,4-glycosidic bonds by the action of glycogen
synthase (GS) (10,11). There are two GS isoforms in
mammals encoded by separate genes. GYS1, encoding the
muscle isoform, is expressed in muscle and many other
organs, including kidney, heart, and brain, whereas GYS2,
encoding the liver GS isoform, is expressed exclusively in
the liver (11). GS activity of both isoforms is regulated by
G6P, an allosteric activator, and by covalent phosphory-
lation, which inhibits enzyme activity (10).
Carling and Hardie (12) reported that AMPK phosphor-
ylates muscle GS at site 2 (Ser8 [amino acid numbering
starts from the initiator methionine residue] in human,
mouse, and rat), a known inhibitory site of the enzyme, in
cell-free assays. Recent work has shown in intact skeletal
muscle tissue that acute stimulation of AMPK by a phar-
macologic activator, 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR), promotes phosphorylation of
GS at site 2 (13), resulting in a decrease in enzymatic
activity (13–15). From these ﬁndings, it was anticipated
that activation of AMPK would reduce muscle glycogen
levels. However, in apparent conﬂict with this antici-
pation, long-term/chronic activation of AMPK increases
glycogen storage in skeletal (16,17) and cardiac (18) mus-
cles. Some have speculated that AMPK-mediated increases
in glucose transport and the subsequent elevation of intra-
cellular [G6P] are able to allosterically stimulate GS and
thus glycogen synthesis by overriding the inhibitory phos-
phorylation of GS in muscles (8,9).
This hypothesis, however, has not been directly tested,
mainly because there are currently no experimental or
assay systems to assess G6P-mediated regulation of GS in
vivo. GS activity is routinely assayed in vitro using cell/
tissue extracts in which the rate of incorporation of UDP-
[
14C]glucose into glycogen is measured in the absence or
presence of G6P (19). GS activity in the presence of sat-
urating concentrations of G6P is independent of the state
of phosphorylation, and the activity ratio in the absence of
From the
1MRC Protein Phosphorylation Unit, College of Life Sciences, Uni-
versity of Dundee, Dundee, U.K.; and the
2Molecular Physiology Group,
Department of Exercise and Sport Sciences, University of Copenhagen,
Copenhagen, Denmark.
Corresponding author: Roger W. Hunter, r.x.hunter@dundee.ac.uk.
Received 13 August 2010 and accepted 24 December 2010.
DOI: 10.2337/db10-1148
This article contains Supplementary Data online at http://diabetes.
diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1148/-/DC1.
 2011 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
766 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.org
ORIGINAL ARTICLEG6P relative to that in the presence of G6P is used as an
index of GS activity. However, it has been virtually im-
possible to prove that G6P activates GS in vivo or to as-
sess its physiologic signiﬁcance because G6P binds
noncovalently to GS and therefore dissociates from it
when muscle tissue is homogenized in a protein extraction
buffer.
We have recently identiﬁed a key residue, Arg582, which
is located in a highly basic segment comprising a putative
G6P-binding pocket at the C-terminus of GS (20,21). Sub-
stitution of Arg582 to Ala (R582A) caused a complete loss
of allosteric activation of GS by G6P without affecting
phosphorylation-dependent enzymatic activity and robustly
reduced insulin-mediated glycogen synthesis in skeletal
muscle (22). To investigate the physiologic involvement of
allosteric activation of GS in regulating muscle glycogen
metabolism in vivo, a knock-in mouse expressing a G6P-
insensitive GS mutant (GS
R582A/R582A mouse) has recently
been generated (22). Using this mouse model, we demon-
strate here that acute activation of AMPK promotes mus-
cle glycogen synthesis through allosteric activation of GS
through increasing glucose uptake and the subsequent rise
in intracellular [G6P].
RESEARCH DESIGN AND METHODS
Materials. D-[U-
14C]glucose-1-phosphate was purchased from Hartmann An-
alytic GmbH (Brunswick, Germany). All other radiochemicals were from
Perkin Elmer (Buckinghamshire, U.K.). Human insulin (Actrapid) was from
Novo-Nordisk (Bagsværd, Denmark). AICAR was from Toronto Research
Chemicals (Ontario, Canada). Wortmannin was from Tocris (Avonmouth, U.K.).
Horseradish peroxidase-conjugated secondary antibodies were from Thermo
Fisher (Northumberland, U.K.). All other chemicals, unless speciﬁed otherwise,
were obtained from Sigma (Poole, U.K.).
Animals. Animal studies were approved by the University of Dundee Ethics
Committee and performed under a U.K. Home Ofﬁce project license. C57BL/6 J
mice were obtained from Harlan (Leicestershire, U.K.). Generation of the
muscle GS
R582A/R582A knock-in (22) and transgenic AMPK kinase dead (K45R)
(23) mice has been previously described.
Antibodies. Total acetyl CoA carboxylase (ACC), phospho ACC1 (Ser
79, also
detects equivalent site on mouse ACC2 at Ser
212), total raptor, phospho raptor
(Ser
792), total glycogen synthase (GS), phospho GS (Ser
641), total AMPKa,
phospho AMPKa (Thr
172), and phospho protein kinase B (PKB; Thr
308)a n t i -
bodies were from Cell Signaling Technology (Beverly, MA). Hexokinase II
antibody (C-14) was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). The phospho GS antibodies (Ser
8 and Ser
8/11) (24) and the total AMPKa1
and AMPKa2 antibodies used for immunoprecipitation were generated and
donated by Professor D. Grahame Hardie (University of Dundee). GLUT4
antibody was generated and donated by Professor Geoffrey Holman (Uni-
versity of Bath). Generation of the TBC1D1 (total [S279C, 1st bleed] and
antiphospho Ser
231 [S131C, 2nd bleed]) (25), phosphorylase (total [S956A, 2nd
bleed] and antiphospho Ser
15 [S960A, 1st bleed]), and total PKBa (S742B,
2nd bleed) antibodies (26) has been previously described.
Incubation of isolated muscle. Mice were killed by cervical dislocation, and
extensor digitorum longus (EDL) muscles were rapidly removed and mounted
on an incubation apparatus as described (26). Muscles were incubated in 2 mL
Krebs-Ringer bicarbonate (KRB) buffer (in mmol/L: 117 NaCl, 4.7 KCl,
2.5 CaCl2,1 . 2K H 2PO4,1 . 2M g S O 4, and 24.6 NaHCO3, pH 7.4) containing
5.5 mmol/L D-glucose for 40 min at 37°C gassed continuously with 95% O2
and 5% CO2. At the end of the incubation period muscles were frozen in liquid
nitrogen and stored at 280°C.
Measurement of glucose transport. EDL muscles were isolated and 2-deoxy-
[
3H]glucose uptake was measured as described (27). Brieﬂy, muscles were
incubated in 2 mL KRB containing 2 mmol/L pyruvate for 40 min at 37°C.
Muscles were transferred to 2 mL KRB containing 1 mmol/L 2-deoxyglucose
(1.5 mCi/mmol 2-deoxy-D-[1,2-
3H(N)]glucose) and 7 mmol/L D-mannitol (0.064
mCi/mmol D-[1-
14C]mannitol) and incubated for an additional 10 min at 30°C.
Muscles were frozen in liquid nitrogen and acid hydrolysates subjected to
scintillation counting (27).
Measurement of glycogen synthesis. D-[U-
14C]glucose incorporation into
muscle glycogen was determined as previously described (26). Brieﬂy, EDL
muscles were incubated in 2 mL KRB containing 5.5 mmol/L D-glucose and
0.1 mCi/mmol D-[U-
14C]glucose for 40 min at 37°C. Muscles were frozen in
liquid nitrogen and [
14C]glycogen extracted by ethanol precipitation from KOH
digests as described (26).
Measurement of glycolysis. The rate of glycolysis was determined by the
detritiation of [5-
3H]glucose as described (22). Brieﬂy, muscles were incubated
in 2 mL KRB containing 5.5 mmol/L glucose and 0.5 mCi/mmol [5-
3H]glucose
for 40 min at 37°C. Muscles were frozen in liquid nitrogen, and the rate of
[5-
3H]glucose incorporation into glycogen was determined as described for
D-[U-
14C]glucose. [
3H]H2O was isolated from conditioned KRB by borate com-
plex ion exchange chromatography and measured by scintillation counting.
Preparation of muscle lysates. Muscle lysates were prepared as described
(26). Homogenates were clariﬁed at 3,000g for 10 min at 4°C, and protein
concentration was estimated using Bradford reagent and bovine serum al-
bumin (BSA) as standard. Lysates were frozen in liquid nitrogen and stored
at 280°C.
Immunoblotting. Muscle extracts (20–30 mg) were denatured in SDS sample
buffer, separated by SDS-PAGE, and transferred to polyvinylidene ﬂuoride
membrane. Membranes were blocked for 1 h in 20 mmol/L Tris-HCl (pH 7.5),
137 mmol/L NaCl, and 0.1% (v/v) Tween-20 (TBST) containing 5% (w/v)
skimmed milk. Membranes were incubated in primary antibody prepared in
TBST containing 5% (w/v) BSA overnight at 4°C. Detection was performed
using horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence reagent.
Assay of glycogen synthase and phosphorylase. Muscle homogenates (25
mg) were assayed for glycogen synthase and phosphorylase activity (reverse
direction) by measuring the incorporation of UDP-[U-
14C]glucose and [U-
14C]
glucose-1-phosphate respectively into glycogen, as described (22). Results are
expressed as the activity ratio in the absence and presence of 10 mmol/L G6P
(glycogen synthase) or 2 mmol/L AMP (phosphorylase).
AMPK activity assay. AMPK was immunoprecipitated from 30 mg lysate with
antibodies against the a1 and a2 subunits and assayed for phosphotransferase
activity toward AMARA peptide (AMARAASAAALARRR) using [g-
32P]ATP, as
previously described (28).
Assay of muscle glycogen. Frozen muscles were digested in 100 mL of 1 mol/L
KOH for 20 min at 80°C. The pH was adjusted to 4.8 with 50 mL of 4 mol/L
acetic acid and 250 mL of 4 units/mL amyloglucosidase (Aspergillus niger)i n
0.2 mol/L sodium acetate (pH 4.8 added). Samples were incubated for 2 h at
40°C, clariﬁed at 16,000g for 10 min, and neutralized with NaOH. Glucose
released from glycogen was determined using a commercial hexokinase/G6P
dehydrogenase (G6PDH) coupled assay (Amresco, Solon, OH) using D-glucose
as a standard.
Assay of muscle G6P. G6P was assayed ﬂuorometrically in HClO4 extracts of
EDL muscle, as previously described (22).
Statistical analyses. Data are expressed as means 6 SEM. Statistical analysis
was performed by unpaired, two-tailed Student t test or one-way or two-way
ANOVA with Dunnett post hoc test. Differences between groups were con-
sidered statistically signiﬁcant when P , 0.05.
RESULTS
Pharmacologic activation of AMPK leads to
inactivation of muscle glycogen synthase. We ﬁrst
measured the effect of the pharmacologic AMPK activator,
AICAR, on AMPK activity in EDL muscle (composed
mainly of fast-twitch, glycolytic ﬁbers) isolated from male
C57BL/6 mice. EDL was used because the effects of AICAR
on AMPK activity and glucose uptake are reported to be
robust in this muscle (29). As previously reported (27),
incubation of EDL ex vivo with AICAR promoted robust
phosphorylation of the AMPKa catalytic subunit at Thr172
in the T-loop and activation of both AMPKa1( ;twofold)
and AMPKa2( ;fourfold) compared with unstimulated
muscle (Fig. 1A and B). Consistent with these observa-
tions, AICAR treatment increased phosphorylation of
known AMPK substrates such as ACC2 at Ser212, raptor at
Ser792 (30), and TBC1D1 at Ser231 (25,31) (Fig. 1B).
We next assessed the effect of AICAR on phosphoryla-
tion and activity of GS in isolated EDL muscle. Muscles
were incubated in parallel with GS-activating (insulin) and
GS-inhibiting (adrenaline) hormones as controls. AICAR
treatment resulted in a modest but signiﬁcant decrease in
GS activity (;10%) (Fig. 2A). However, in contrast to
previous studies (13,14), no detectable change in the
phosphorylation of GS at Ser8, an inhibitory site that is
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phosphorylation of Ser8 is known to promote subsequent
phosphorylation of Ser11 by casein kinase 1, which cannot
be detected by Ser8 phospho-speciﬁc antibody, we also
monitored dual phosphorylation of Ser8 and Ser11 by
a phospho-speciﬁc antibody that detects only when both
sites are phosphorylated. AICAR failed to induce a detect-
able change in the phosphorylation of Ser8 and Ser11,
whereas adrenaline robustly increased phosphorylation
of these sites, correlating with a marked decrease in GS
activity (Fig. 2A and B). AICAR did not modify phos-
phorylation of other key regulatory sites such as Ser641,
whereas insulin promoted dephosphorylation of this site
likely via the PKB/GS kinase 3 (GSK3) pathway (Fig. 2B),
resulting in a ;1.7-fold increase in GS activity (Fig. 2A and
B), as previously reported (32).
AICAR stimulates muscle glycogen synthesis
independent of the phosphoinositide-3 kinase pathway.
A well-established physiologic role of AMPK in muscle is
to stimulate glucose transport (5). Incubation of EDL with
AICAR or insulin signiﬁcantly increased 2-deoxy-[
3H]glucose
uptake by ;twofold and ;1.5-fold, respectively (Fig. 3A).
AICAR also caused an increase (2.5-fold) in the levels
of G6P compared with resting EDL (Fig. 3B). Although
chronic/continuous AICAR treatment is known to pro-
mote glucose transport and phosphorylation at least par-
tially through an increase in the levels of GLUT4 and
hexokinase II- (16,17) short-term incubation (40 min)
did not cause detectable changes in the amount of these
proteins (Fig. 3E). We next measured glycogen synthe-
sis by monitoring incorporation of D-[
14C-U]glucose into
glycogen in response to AICAR or insulin. Both AICAR
and insulin stimulated glycogen synthesis by ;1.6-fold
(Fig. 3C), which was associated with a signiﬁcant in-
crease (1.4-fold) in muscle glycogen concentration
(Fig. 3D).
The effect of AICAR on both glucose uptake and gly-
cogen synthesis was distinct from those by insulin, and the
phosphoinositide-3 kinase pathway as wortmannin, a se-
lective phosphoinositide-3 kinase inhibitor, abolished insulin-
stimulated glucose transport and glycogen synthesis, but
not in response to AICAR (Fig. 4A and B).
AICAR has no effect on muscle glycogen phosphorylase
activity. Net glycogen content and incorporation of [
14C]
glucose are dependent on both glycogen synthesis and
degradation. Consequently, the increased glycogen con-
tent observed in AICAR-treated muscles could be partly
FIG. 1. AICAR robustly stimulates activation of AMPK in EDL muscle.
EDL muscles from male C57BL/6J mice (7–10 weeks old) were in-
cubated with vehicle or 2 mmol/L AICAR for 40 min in KRB containing
5.5 mmol/L glucose. A: AMPK was immunoprecipitated from muscle
lysates using anti-AMPKa1 or anti-AMPKa2 antibodies and assayed for
activity using AMARA peptide. Assays were performed in duplicate
from muscles derived from four mice and are expressed as mean 6
SEM. B: Lysates were immunoblotted to assess phosphorylation of
components of the AMPK pathway. Results are representative of
experiments performed on tissues from at least three mice. *P < 0.05.
FIG. 2. AICAR modestly inhibits GS activity in vitro. EDL muscles from
C57BL/6J mice were incubated with vehicle, 2 mmol/L AICAR, 10 mU/
mL insulin, or 10 mmol/L adrenaline for 40 min in KRB containing 5.5
mmol/L glucose. A: GS activity was measured in muscle homogenates as
described in RESEARCH DESIGN AND METHODS. Results are presented as
mean 6 SEM from the indicated number (n) of mice. B: Alternatively,
lysates were immunoblotted for GS phosphorylation with the indicated
antibodies. *P < 0.05 compared with basal.
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possibility, we assessed the activity of muscle glycogen
phosphorylase, a rate-limiting enzyme in glycogen degra-
dation. Phosphorylase activity and phosphorylation at
Ser15, an activating residue that is catalyzed by phos-
phorylase kinase, were both unchanged in response to
AICAR or insulin (Fig. 5A and B). To conﬁrm that our
assay was sensitive enough to detect changes in phos-
phorylase activity, isolated EDL muscles were also in-
cubated in the presence of adrenaline, an activator of
phosphorylase through a phosphorylase kinase-dependent
pathway. As expected, adrenaline caused a signiﬁcant ac-
tivation of phosphorylase (twofold) that was accompanied
by an increase (;50%) in phosphorylation of Ser15 (Fig.
5B).
Catalytic activity of AMPK is required for AICAR-
stimulated muscle glycogen synthesis. To establish that
AICAR-stimulated glycogen synthesis is mediated through
AMPK and not by off-target action(s) of the compound, we
assessed the effect of AICAR on glycogen synthesis in EDL
from mice expressing catalytically inactive/kinase dead
(KD) AMPKa2 (23). Immunoblot analysis using anti-pan-
AMPKa antibody conﬁrmed that KD AMPK, epitope-tagged
with Myc, displayed a slightly slower mobility and en-
dogenous AMPKa was absent (Fig. 6D). As previously
reported, AMPKa2 activity was largely eliminated, and
AMPKa1 was also substantially reduced at rest in EDL
from AMPK KD animals (Fig. 6A), an effect likely due to the
displacement of endogenous a2 and also a1 from bg het-
erotrimers by over-expressed KD a2, as has previously
been suggested (23). Consistent with previous studies (33),
AICAR signiﬁcantly stimulated both AMPKa1 and AMPKa2
activity in wild-type mice, whereas neither AMPKa1 nor a2
activity was signiﬁcantly increased in muscles from AMPK
KD mice (Fig. 6A). AICAR caused a robust increase in
ACC2 phosphorylation, which was partially suppressed
(;30–40%) in AMPK KD mice (Fig. 6D), as previously
reported (33).
We next measured the effect of AICAR on GS activity in
EDL isolated from AMPK KD or wild-type littermate con-
trol animals. In unstimulated muscles, GS activity was
signiﬁcantly higher (about twofold) in AMPK KD com-
pared with wild-type mice (Fig. 6B), which was associated
with a modest decrease in GS phosphorylation at both
Ser8 and Ser641 (Fig. 6D). AICAR caused a modest (;10%)
decrease in GS activity in wild-type mice but not in AMPK
KD animals, demonstrating that AMPK catalytic activity,
most likely a2 activity (13), is required for GS inactivation
by AICAR (Fig. 6B). AICAR did not signiﬁcantly promote
single Ser8 and dual Ser8/11 phosphorylation in EDL from
wild-type or AMPK KD mice. Insulin promoted GS de-
phosphorylation on Ser641 and activation in muscles of
wild-type and AMPK KD mice to a relatively similar degree
(Fig. 6B and D). Insulin did not cause a signiﬁcant change
in Ser8 phosphorylation, although some muscle showed
a slightly reduced phospho signal on this site (Fig. 6D). We
next measured glycogen synthesis and observed that
AICAR-stimulated increases were abolished in AMPK KD
animals, whereas insulin stimulated glycogen synthesis in
both genotypes to the same extent (Fig. 6C). Total protein
expression and phosphorylation of phosphorylase was
similar between wild-type and AMPK KD muscles in both
resting and AICAR-treated mice (Fig. 6D).
Allosteric activation of GS is required for AICAR-
stimulated muscle glycogen synthesis. To establish that
AICAR-stimulated glycogen synthesis is mediated through
allosteric activation of GS by G6P, we have used G6P-
insensitive GS knock-in mice in which a critical G6P per-
missive residue (Arg582) is changed to Ala (GSR582A/R582A).
We have recently reported that mutant GS derived from
GS
R582A/R582A mouse skeletal muscle is completely resis-
tant to G6P but retains its capacity to be activated through
dephosphorylation by GSK3 inhibition in response to
insulin (22).
As reported previously, glycogen synthesis in resting
EDL was comparable between wild-type and GS
R582A/+
mice, and there was a substantial decrease (;70–80%) in
glycogen synthesis in GS
R582A/R582A animals compared with
wild-type or GS
R582A/+. AICAR stimulated glycogen syn-
thesis in wild-type and GS
R582A/+ mice by ;twofold and
;1.5-fold, respectively, whereas AICAR had no effect on
glycogen synthesis in GS
R582A/R582A animals (Fig. 7A).
There was a trend that AICAR modestly inhibited glycogen
synthesis in GS
R582A/R582A mice, possibly through de-
activation of GS or stimulation of phosphorylase. To rule
FIG. 3. AICAR stimulates glucose uptake and storage into glycogen.
EDL muscles from C57BL/6J mice were incubated with vehicle, 2 mmol/
L AICAR, or 10 mU/mL insulin for 40 min in KRB containing 2 mmol/L
pyruvate. A: Muscles were transferred to vials containing 2-deoxy-[
3H]
glucose and glucose transport assayed as described in RESEARCH DESIGN
AND METHODS. B: Alternatively, EDL muscles incubated with vehicle
or 2 mmol/L AICAR for 40 min were snap frozen in liquid nitrogen
and glucose-6-phosphate (G6P) levels assayed as described in RESEARCH
DESIGN AND METHODS. C: Isolated EDL muscles were incubated with
the indicated stimuli for 40 min in KRB containing D-[U-
14C]glucose (5.5
mmol/L), and the rate of glucose incorporation into glycogen was de-
termined as described in RESEARCH DESIGN AND METHODS. D: Alternatively,
EDL muscles were incubated in KRB containing unlabeled glucose (5.5
mmol/L) for 1 h, and glycogen content was determined by digestion of
KOH extracts with amyloglucosidase as described in RESEARCH DESIGN AND
METHODS. E: EDL muscles were incubated with vehicle or 2 mmol/L
AICAR for 40 min and lysates immunoblotted with the indicated anti-
bodies. Results are presented as mean 6 SEM from the indicated
number (n) of mice. *P < 0.05 compared with basal.
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observed in GS
+/R582A and GS
R582A/R582A mice was caused
by reduced glucose transport or altered AMPK activity, or
both, these parameters were measured in isolated EDL
muscle in the presence or absence of AICAR. We observed
no difference in basal or in AICAR-stimulated glucose
uptake across all genotypes (Fig. 7B). We also conﬁrmed
that resting and AICAR-stimulated AMPK activity (a1 and
a2) were similar between wild-type and GS
R582A/R582A mice
(Fig. 7C).
Interestingly, despite the signiﬁcant impairment in gly-
cogen synthesis, overall glucose utilization, as determined
by metabolism of [5-
3H]glucose was also similar between
wild-type and GS
R582A/R582A mice (Fig. 7D). The decrease
in glycogen synthesis in GS
R582A/R582A mice was compen-
sated by a signiﬁcant increase in the rate of glycolysis in
both resting and AICAR-stimulated muscles. Consistent
with this ﬁnding, the rate of lactate release was also ele-
vated under resting and AICAR-stimulated conditions in
GS
R582A/R582A mice compared with wild-type (Fig. 7E). We
conﬁrmed that GS activity in resting EDL muscles was
comparable between wild-type and GS
R582A/R582A mice
when assayed in the absence of G6P, whereas the robust
G6P-mediated activation observed in wild-type mice was
completely abolished in the muscle of GS
R582A/R582A mice
(Fig. 7F). AICAR modestly deactivated muscle GS in both
wild-type and GS
R582A/R582A animals (Fig. 7F). Potentially,
hypophosphorylation of GS by inhibition of GSK3 may
compensate for the lack of allosteric activation by G6P in
GS
R582A/R582A mice. Accordingly, we co-incubated EDL
muscle with AICAR and the GSK3 selective inhibitor,
CT99021, and observed a signiﬁcant, albeit modest in-
crease in glycogen synthesis compared with muscle
treated with AICAR alone (Supplementary Fig. 1).
DISCUSSION
We (8) and others (16,17) previously reported that AICAR
treatment caused an increase in muscle glycogen levels;
however, whether this was mediated through AMPK has
not been clearly demonstrated. AICAR (Z-riboside) is
a widely used AMPK activator that is taken up into cells by
adenosine transporters and converted by adenosine kinase
to the monophosphorylated derivative ZMP (34). ZMP
binds to the g subunit of AMPK and mimics the effect of
AMP on the allosteric activation of the kinase and also on
inhibition of dephosphorylation (35). However, because
AICAR has been found to produce AMPK-independent
effects due to binding of ZMP to other AMP/ZMP-regulated
enzymes and also to unknown off-target effects (34), we
wished to establish that AICAR-stimulated glycogen syn-
thesis occurs in an AMPK-dependent manner.
FIG. 4. AICAR-stimulated glucose disposal is independent of phosphoinositide-3 (PI-3) kinase. EDL muscles from C57BL/6J mice were incubated
with vehicle (0.2% DMSO) or 100 nmol/L wortmannin for 20 min in KRB/pyruvate. A: Muscles were transferred to fresh KRB/glucose containing
matched vehicle/compound and the indicated stimuli for 40 min. Finally, glucose transport was assayed using 2-deoxy-[
3H]glucose as described in
RESEARCH DESIGN AND METHODS. B: Alternatively, muscles preincubated with vehicle or wortmannin as described in (A) were transferred to KRB
containing D-[U-
14C]glucose (5.5 mmol/L) and the indicated stimuli and incubated for 40 min. The rate of glucose incorporation into glycogen was
determined as described in RESEARCH DESIGN AND METHODS. Results are expressed as mean 6 SEM from the indicated number (n) of mice. *P < 0.05
compared with basal.
FIG. 5. AICAR has no effect on glycogen phosphorylase activity in vitro.
EDL muscles were treated as described in Fig. 2 and lysates were
assayed for phosphorylase activity (A) or immunoblotted with the in-
dicated antibodies (B). Results are presented as mean 6 SEM from the
indicated number (n) of mice. *P < 0.05 compared with basal.
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speciﬁc activator of AMPK, the thienopyridine A-769662,
which is a useful tool to understand the physiologic
consequences of AMPK activation in animals (36–38).
However, Scott et al. (39) have demonstrated that this
compound selectively activates b1-containing AMPK tri-
meric (abg) complexes, but not b2-complexes in cell-
free assays. They further investigated the selectivity of
A-769662 in vivo and showed that A-769662 failed to
stimulate AMPK in AMPKb1-deﬁcient mouse tissues (39).
The two b1-containing AMPK heterotrimers (a1b1g1a n d
a2b1g1), as well as activity associated with these com-
plexes, appear to constitute only a small fraction of the
total pool of AMPK trimeric complex/activity (i.e., ,5%)
in mouse skeletal muscle (40). A-769662 treatment
resulted in only a modest activation of AMPK (37,39) and
failed to promote AMPK-dependent increases in glucose
uptake in isolated mouse skeletal muscles (40). There-
fore, A-769662 would not be a suitable tool to study the
effect of AMPK on glucose/glycogen metabolism in mouse
skeletal muscle. As an alternative approach, we used a
genetically engineered mouse model, AMPK KD, in which
AMPK is inactivated by transgenic over-expression of a
dominant inhibitory AMPKa2 mutant in muscle cells (6),
and established that catalytic activity of AMPK is neces-
sary to elicit AICAR-stimulated glycogen synthesis most
likely by increased glucose transport and subsequent ac-
cumulation of intracellular G6P.
Consistent with previous studies, AICAR modestly de-
creased the muscle GS activity ratio (13,15), a measure of
phospho-dependent activity, in cell-free assays in wild-type
animals, and this effect was lost in AMPK KD mice.
However, we failed to detect a consistent elevation in GS
phosphorylation at site 2 (Ser8) or site 2 + 2a (Ser8 and
Ser11) in EDL incubated with AICAR ex vivo. These anti-
bodies have been stringently validated (24), so it would
appear that the effect of AICAR on site 2 phosphorylation
is modest (as evidenced by only ;10% decrease in GS
FIG. 6. AICAR-stimulated glycogen synthesis is AMPK-dependent. A: Isolated EDL muscles from 14- to 18-week-old wild-type (WT, □) or AMPKa2
KD mice (▨) were incubated with the indicated stimuli for 40 min, and AMPK activity was determined as described in Fig. 1. B: Alternatively,
muscles were incubated with the indicated stimuli for 40 min in KRB containing 5.5 mmol/L glucose and GS activity measured in tissue
homogenates, as described in RESEARCH DESIGN AND METHODS. C: Muscles were incubated with the indicated stimuli for 40 min in KRB containing
D-[U-
14C]glucose (5.5 mmol/L), and the rate of glucose incorporation into glycogen was determined as described in RESEARCH DESIGN AND METHODS.
D: Muscles from WT and AMPKa2 KD mice were incubated with the indicated stimuli for 40 min and tissue lysates immunoblotted with the
indicated antibodies. Results are presented as mean 6 SEM from the indicated number (n)o fm i c e .* P < 0.05.
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(22). EDL muscles from the indicated genotypes were incubated with vehicle or 2 mmol/L AICAR in KRB containing D-[U-
14C]glucose (5.5 mmol/L)
AMPK IN CONTROL OF MUSCLE GLYCOGEN STORAGE
772 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgactivity), and in the current study, it failed to reach sta-
tistical signiﬁcance.
This modest effect of AICAR on GS phosphorylation
probably explains why a previous study failed to observe
signiﬁcant GS inhibition in skeletal muscle (8). A more
robust effect of AICAR on GS activity and phosphorylation
has been observed in rat skeletal muscle, although the
reason for this is unclear (13). We tested if G6P directly
affected GS phosphorylation by AMPK in response to
AICAR. AMPK-mediated Ser8 phosphorylation of GS was
not signiﬁcantly altered in the presence of G6P in cell-free
assays, although supraphysiologic concentrations of G6P
(2 mmol/L) modestly reduced GS Ser8 phosphorylation by
AMPK (Supplementary Fig. 2). Although we cannot com-
pletely rule out the possibility that AMPK inactivates GS
through phosphorylation at other site(s), apart from Ser8,
a previous in vitro phospho-mapping study did not identify
additional phosphorylation sites (12). In support of this,
there were no other obvious AMPK target site(s) (the
typical consensus motif is fX[B, X)XX(Ser/Thr]XXXf,
where f is a hydrophobic residue, B is basic, and X is any
residue) (1) on GS when motif scan analysis (Scansite,
http://scansite.mit.edu/) was performed. Regardless of the
mechanism, the modest inactivation of GS by AMPK was
overridden by the allosteric stimulator, G6P, resulting in
elevated GS activity in vivo as evidenced by an increase in
[
14C]glucose incorporation into glycogen.
Gain-of-function mutation in AMPKg1 (R70Q) (41) and
naturally occurring mutations in g3 (R200Q) originally
identiﬁed in the Hampshire pig (Sus scrofa domesticus;
RN-) (42), are known to promote marked glycogen accu-
mulation in skeletal muscle. In addition, mutations in the
AMPKg2 subunit (encoded by the PRKAG2 gene) have
been implicated in the human cardiomyopathy, Wolff-
Parkinson-White syndrome, which is characterized by
ventricular pre-excitation, and in certain cases, cardiac
hypertrophy (18). Notably, several genetic studies have
revealed that g2 mutations cause excess myocardial
glycogen accumulation (43–45), which is hypothesized
to cause conduction system abnormalities by unknown
mechanism(s) (18,46). Interestingly, Luptak et al. (9) dem-
onstrated that transgenic mice over-expressing one of the
g2 mutations (N488I) in cardiomyocytes displayed aberrant
high activity of AMPK resulting in elevated intracellular
[G6P] due to increased glucose uptake, which serves as
both the carbon skeleton for glycogen synthesis and the
allosteric stimulator of GS. It would be of major interest
to cross AMPKg2 mutant transgenic animals with G6P-
resistant GS
R582A/R582A knock-in mice and investigate if
abnormal cardiac glycogen accumulation and the asso-
ciated pathologies can be rescued.
In summary, we provide genetic evidence that AMPK-
mediated glycogen synthesis occurs by increased activity
of GS through its allosteric stimulator, G6P, and we pro-
pose the following model (Fig. 8): elevated glucose trans-
port promoted by increased AMPK activity causes an
accumulation of intracellular G6P. This leads to allosteric
activation of GS, which overrides the inhibitory effect of
AMPK on GS resulting in a net increase in GS activity and
excess glycogen storage in muscle cells. Our work is of
particular importance when considering AMPK as a target
for treating metabolic disorders such as type 2 diabetes
(47) because chronic/persistent activation of AMPK may
have adverse consequences on cardiac function.
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